Newsflash:
- Many Drug Labels Missing Dose, Safety Info for Kids
- Lilly Oncology to Highlight Final Results for Phase III Study in Most Common Form of Lung Cancer
- J&J Opens Doxil Rationing Program to New Patients
- FDA Issues Safety Label Changes for Fingolimod
- FDA Backs Pill to Block HIV Infection
- FDA Advisers Recommend Approving Arena Weight-Loss Drug
Amylin Outlines Corporate Strategy to Maximize Global Value of Diabetes Franchise and Advance Key Pipeline Candidates
Amylin Pharmaceuticals Press Release (01/09/12)
In a presentation at the 30th Annual J.P. Morgan Healthcare Conference, Amylin President and CEO Daniel M. Bradbury highlighted steps the company is taking to prepare for the planned U.S. launch this quarter of the investigational medication BYDUREON (exenatide extended-release for injectable suspension), which is currently under review by the FDA and has a Prescription Drug User Fee Action date of Jan. 28, 2012. In addition, Bradbury unveiled the company's 2012 goals to realize the global value of its exenatide franchise, maximize the contribution from marketed products BYETTA (exenatide) injection and SYMLIN (pramlintide acetate) injection, and advance its late-stage product pipeline.
Abstract News © Copyright 2011
INFORMATION, INC.
Sponsor Highlights
Our Sponsors:
Sitemap
© Pharmacist e-Link
